Related to Eleven Increases Series A Fundraising to $45M for Protein Therapeutics Pipeline

• Alcon Gains AstraZeneca’s Ophthalmology Compound Library
  
• NicOx Reacquires Nitric Oxide-Donating Ophthalmology Compounds from Pfizer
  
• Otsuka Inks Six-Month Extension to Research Deal with MethylGene in Ocular Diseases
  
• Alcon Picks Up ESBATech’s Opthalmology Franchise for $150M Up Front
  
• Ambrx and Wyeth Sign Multitarget Alliance to Develop Protein Drugs
  
• Enzo Teams Up with NIH National Eye Institute for Clinical Trial with Optiquel
  
• Sanofi-Aventis Inks $539M Deal to Purchase Fovea
  
• Genentech a Step Closer to Expanding Label for Eye Disease Therapy Lucentis
  
• SurModics Obtains $3.5M Up Front in Ophthalmic Deal with Roche and Genentech
  
• Alcon Takes On Potentia’s AMD Therapy and Gains Option Related to Other Retinal Diseases
  
• Molecular Partners Raises Almost $45M to Support Phase II Trials in Ophthalmology
  
• BTG Grants Allergan Rights to Gel-Based Drug-Delivery Technology for Use in Ocular Disease Treatment
  
• Novartis Plans Full Takeover of Alcon for $39.3B
  
• EyeGate Secures $22.6M to Continue Clinical Development of Iontophoretic Eye Therapy
  
• RXi Partners with University of Massachusetts Med School on RNAi Therapeutics for Ocular Disease
  
• Alcon Buys Ophthalmic Pharmaceutical Assets from Sirion
  
• Alcon Concludes Novartis’ $11.2B Acquisition Bid Is Grossly Inadequate
  
• GSK Pays Apeiron About $17.5M Up Front for Early Clinical-Stage ACE2 Candidate
  
• Schepens Eye Institute Receives Unrestricted Grant to Progress Retinal Stem Cell Collaboration with ReNeuron
  
• Genzyme and Arecor Ally to Advance Protein Therapeutics